Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM EDTCowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.
With this approval the... More
Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval
October 4, 2017 7:27 AM EDTBTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy rating after the company received final FDA approval for its generic versions of Tevas (NASDAQ: TEVA) 20mg and 40mg... More
Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho
October 4, 2017 7:02 AM EDTMizuho analyst Irina Koffler weighed in on Mylan's (NASDAQ: MYL) surprise approval for generic Copaxone after downplaying the possibility of a September approval and taking Copaxone out of its 2017 estimates. Koffler sees the news as "quite negative" Teva Pharma (NYSE: TEVA).
On Mylan, Koffler notes, "Importantly, Copaxone is AP rated (or therapeutically equivalent and substitutable), which makes it easier to... More
Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:42 AM EDTMomenta Phama (NASDAQ: MNTA) shares were in focus after Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone. Shares declined pre-market, along with Teva Pharma (NYSE: TEVA).
... MoreTeva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone
October 4, 2017 6:14 AM EDTTeva (NYSE: TEVA) shares declined after Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone. Shares declined 9% pre-market.
... More